Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Remo H. M. Furtado"'
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
Externí odkaz:
https://doaj.org/article/b02c1352158d4432b01234f9b4cd67f3
Publikováno v:
Cardiology and Therapy, Vol 9, Iss 1, Pp 59-73 (2020)
Abstract For more than half a century, low-density lipoprotein cholesterol (LDL-C) has been recognized as a major risk factor for incident atherosclerotic cardiovascular disease. The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9)
Externí odkaz:
https://doaj.org/article/b9dd8b22b97b4b579647e4b62a14417e
Autor:
Paulo R. Rizzo Genestreti, Remo H. M. Furtado, Rocio Salsoso, Talia F. Dalçóquio, Andre Franci, Fernando R. Menezes, Cesar Caporrino, Aline G. Ferrari, Carlos A. K. Nakashima, Marco A. Scanavini Filho, Felipe G. Lima, Roberto R. C. V. Giraldez, Luciano M. Baracioli, Jose C. Nicolau
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 19, p 5776 (2022)
Background: The management of acute myocardial infarction (AMI) presents several challenges in patients with diabetes, among them the higher rate of recurrent thrombotic events, hyperglycemia and risk of subsequent heart failure (HF). The objective o
Externí odkaz:
https://doaj.org/article/b29b43d1af614a5c84af49849177b0f8
Autor:
Remo H. M. Furtado, Ramkumar V. Venkateswaran, Jose C. Nicolau, Yared Gurmu, Deepak L. Bhatt, Robert F. Storey, P. Gabriel Steg, Giuglia Magnani, Shinya Goto, Mikael Dellborg, Gabriel Kamensky, Daniel Isaza, Philip Aylward, Per Johanson, Marc P. Bonaca
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 10 (2020)
Background A proposed cause of dyspnea induced by ticagrelor is an increase in adenosine blood levels. Because caffeine is an adenosine antagonist, it can potentially improve drug tolerability with regard to dyspnea. Furthermore, association between
Externí odkaz:
https://doaj.org/article/6384ab839e054078afa8fae396ae37f5
Autor:
Marco Antonio Scanavini-Filho, Otavio Berwanger, Wilson Matthias, Miguel O. Aguiar, Hsu P. Chiang, Luciene Azevedo, Luciano M. Baracioli, Felipe G. Lima, Remo H. M. Furtado, Talia F. Dalcoquio, Fernando R. Menezes, Aline G. Ferrari, Fabio de Luca, Robert P. Giugliano, Shaun Goodman, José C. Nicolau
Publikováno v:
Advances in Therapy. 39:1832-1843
Autor:
Devika Aggarwal, Kirtipal Bhatia, Zainali S Chunawala, Remo H M Furtado, Debabrata Mukherjee, Simon R Dixon, Vardhmaan Jain, Sameer Arora, Thomas A Zelniker, Eliano P Navarese, Gregory J Mishkel, Cheong J Lee, Subhash Banerjee, Sripal Bangalore, Justin P Levisay, Deepak L Bhatt, Mark J Ricciardi, Arman Qamar
Publikováno v:
European Heart Journal Open. 2
Aim To compare the efficacy and safety of P2Y12 inhibitor or aspirin monotherapy for secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD). Methods and results Medline, Embase, and Cochrane Central databases were search
Autor:
Devika, Aggarwal, Kirtipal, Bhatia, Zainali S, Chunawala, Remo H M, Furtado, Debabrata, Mukherjee, Simon R, Dixon, Vardhmaan, Jain, Sameer, Arora, Thomas A, Zelniker, Eliano P, Navarese, Gregory J, Mishkel, Cheong J, Lee, Subhash, Banerjee, Sripal, Bangalore, Justin P, Levisay, Deepak L, Bhatt, Mark J, Ricciardi, Arman, Qamar
Publikováno v:
European heart journal open. 2(2)
To compare the efficacy and safety of P2YMedline, Embase, and Cochrane Central databases were searched to identify randomized trials comparing monotherapy with a P2YP2Y
Autor:
Mikhail N Kosiborod, Russell Esterline, Jan Oscarsson, Samvel B Gasparyan, Remo H M Furtado, Subodh Verma, Otavio Berwanger
Publikováno v:
The Lancet. Diabetes & Endocrinology
Autor:
Remo H M, Furtado, Marc P, Bonaca, Itamar, Raz, Thomas A, Zelniker, Ofri, Mosenzon, Avivit, Cahn, Julia, Kuder, Sabina A, Murphy, Deepak L, Bhatt, Lawrence A, Leiter, Darren K, McGuire, John P H, Wilding, Christian T, Ruff, Jose C, Nicolau, Ingrid A M, Gause-Nilsson, Martin, Fredriksson, Anna Maria, Langkilde, Marc S, Sabatine, Stephen D, Wiviott
Publikováno v:
Circulation. 139(22)
Sodium glucose transporter-2 inhibitors reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus and a history of atherosclerotic cardiovascular disease. Because of their baseline risk, patients with pre
Autor:
Remo H M, Furtado, Robert P, Giugliano, Talia F, Dalcoquio, Flavia B B, Arantes, Carlos J D G, Barbosa, Paulo R R, Genestreti, André, Franci, Fernando R, Menezes, Carlos A K, Nakashima, Marco A, Scanavini Filho, Aline G, Ferrari, Rocio, Salsoso, Luciano M, Baracioli, Jose C, Nicolau
Publikováno v:
Journal of thrombosis and thrombolysis. 48(2)
Recent reports have suggested that aspirin effect might be influenced by bodyweight, with decreased efficacy in heavier individuals. We investigated the influence of bodyweight on aspirin pharmacodynamics in two independent datasets of patients takin